ChemoCentryx, Inc. (NASDAQ:CCXI) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

According to Zacks, “ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. “

Several other analysts have also issued reports on the stock. BidaskClub lowered shares of ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Friday. Cowen and Company restated a “hold” rating on shares of ChemoCentryx in a research report on Tuesday, August 8th.

Shares of ChemoCentryx (CCXI) traded down 1.72% on Friday, reaching $6.87. The company’s stock had a trading volume of 141,943 shares. The firm’s market cap is $334.61 million. The stock has a 50 day moving average of $9.39 and a 200-day moving average of $7.71. ChemoCentryx has a 12 month low of $4.06 and a 12 month high of $10.80.

ChemoCentryx (NASDAQ:CCXI) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.02. The business had revenue of $8.94 million for the quarter. On average, analysts anticipate that ChemoCentryx will post ($0.90) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “ChemoCentryx, Inc. (CCXI) Raised to Hold at Zacks Investment Research” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/18/chemocentryx-inc-ccxi-raised-to-hold-at-zacks-investment-research.html.

In other news, insider Petrus Bekker sold 30,000 shares of the stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $9.98, for a total transaction of $299,400.00. Following the completion of the sale, the insider now directly owns 65,963 shares in the company, valued at $658,310.74. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last quarter, insiders have sold 223,649 shares of company stock valued at $2,157,360. 26.80% of the stock is currently owned by company insiders.

Several hedge funds have recently bought and sold shares of the company. Wasatch Advisors Inc. raised its stake in ChemoCentryx by 10.3% in the second quarter. Wasatch Advisors Inc. now owns 2,255,438 shares of the biopharmaceutical company’s stock worth $21,111,000 after buying an additional 210,039 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in ChemoCentryx by 14.5% in the second quarter. The Manufacturers Life Insurance Company now owns 22,514 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 2,852 shares in the last quarter. State Street Corp raised its stake in ChemoCentryx by 7.0% in the second quarter. State Street Corp now owns 429,088 shares of the biopharmaceutical company’s stock worth $4,016,000 after buying an additional 27,896 shares in the last quarter. Voya Investment Management LLC raised its stake in ChemoCentryx by 22.8% in the second quarter. Voya Investment Management LLC now owns 15,984 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 2,965 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in ChemoCentryx by 1.1% in the second quarter. Vanguard Group Inc. now owns 1,212,074 shares of the biopharmaceutical company’s stock worth $11,345,000 after buying an additional 13,344 shares in the last quarter. Institutional investors own 49.37% of the company’s stock.

ChemoCentryx Company Profile

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Get a free copy of the Zacks research report on ChemoCentryx (CCXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.